Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers

Abstract

Introduction: Acute myeloid leukemia (AML) can negatively impact quality of life (QOL). Few QOL instruments are specific to and have been validated in AML. This review aims to identify QOL instruments that have been validated in patients with AML and other cancers and summarize their psychometric properties reported in published literature. A literature review search was performed using PubMed and OVID (Biosis, Embase, MEDLINE) databases through June 25, 2020. Search terms included: QOL, health-related QOL, patient-reported outcomes and validity, reliability, validated, tools, instruments, testretest, and leukemia myeloid acute, leukemia, myeloid, acute, acute myeloid leukemia. Articles were included if they focused on cancer and reported psychometric properties that could be extracted. Abstracts and their references were reviewed for inclusion. Results: Twelve evaluating ten instruments were included. Functional Assessment of Cancer Therapy Leukemia (FACT-Leu) showed internal consistency (IC) of a = 0.86 to >0.9, correlation with EQ-5D-3L of r > 0.50, correlation with European Organisation for Research and Treatment of Cancer (EORTC) QLQ-Leu of r = 0.29-0.63, test-retest reliability of k = 0.861. FACT-F showed correlations with EORTC QLQ-C30 of r = 0.40-0.83. Hematological Malignancy Patient-Reported Outcome (HM-PRO) showed intraclass correlation coefficient (ICC) of 0.94-0.98. EORTC-8D and EQ-5D-3L showed ICC = 0.595, correlations with each other of r = 0.137-0.634 and with EORTC QLQ-C30 of r = 0.651-0.917. EORTC QLQ-C30 showed person separation reliability of 0.47 to 0.90 and patient-observer agreement of 0.85. Life Ingredient Profile (LIP) showed IC of a = 0.29-0.77 and test-retest reliability of k = 0.42-1.0. QOL-E showed correlation with FACT-general of R = 0.71, internal validity of a = 0.7, and test-retest reliability of standardized Cronbach's a = 0.7-0.92. EORTC QLQ-Leu showed IC of a = 0.6-0.79. The Acute Myeloid Leukemia-Quality of Life (AML-QOL) instrument showed IC of a = 0.72, correlations with EORTC QLQ-30 of magnitudes r = 0.59-0.72, and test-retest reliability of ICC = 0.52-0.91.

Health-related quality of life in meningioma

“…Others have also employed cancer-specific instruments to assess HRQOL in meningioma; though these instruments have been historically developed and validated for solid tumor malignancies outside the central nervous system. 14 , 15 Both the cancer- and brain tumor-specific questionnaires have not been validated for the full spectrum of issues relevant to the meningioma population; though the SF-36 has been validated for brain tumor patients, 40% of whom were meningioma patients. 16 With the aforementioned limitations in mind, these instruments still afford structured insight into HRQOL for this subset of brain tumor patients ( Table 1 17–23 ).…”

“… Adapted from 13 , 14 . BCM-20, Brain Cancer Module 2.0; EORTC QLQ-BN20, Quality of Life Questionnaire Brain Neoplasm Module 2.0; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3; EQ-5D, EuroQol 5 Dimension; FACT-BR, Functional Assessment of Cancer Therapy Brain Module; MDASI-BT, M.D.…”

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

“…However, the lack of distinct separation between the treatment groups observed in this study may suggest that AML-specific measures may be better reflective of the HRQoL of these patients. AML-specific QoL measures are in development and their use in future clinical trials may identify the most appropriate outcomes to measure, leading to a better understanding of the impact of the disease and treatment on patients with AML [ 51 , 52 ].…”

Psychometric Properties of MD Anderson Symptoms Inventory for Acute Myeloid Leukemia Patients in Thailand

“…gov (provided by the United State National Library of Medicine) by documenting the patient's perspective, and the importance of AML specific PROMs is highly selective for the EMA and US-FDA drug approval for new further therapeutic agents (Zagadailov et al, 2013). Although several PROMs have been validated, there was a lack of evidence supporting the selected instruments' appropriateness, and more research is needed to determine the most clinically useful instruments in AML patients (DeMuro et al, 2012;Salas et al, 2020).…”